325 related articles for article (PubMed ID: 10087042)
21. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
22. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
[TBL] [Abstract][Full Text] [Related]
23. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Whiteside GT; Harrison JE; Pearson MS; Chen Z; Fundytus ME; Rotshteyn Y; Turchin PI; Pomonis JD; Mark L; Walker K; Broglé KC
J Pharmacol Exp Ther; 2004 Aug; 310(2):793-9. PubMed ID: 15054116
[TBL] [Abstract][Full Text] [Related]
24. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.
Vanderah TW; Largent-Milnes T; Lai J; Porreca F; Houghten RA; Menzaghi F; Wisniewski K; Stalewski J; Sueiras-Diaz J; Galyean R; Schteingart C; Junien JL; Trojnar J; Rivière PJ
Eur J Pharmacol; 2008 Mar; 583(1):62-72. PubMed ID: 18282565
[TBL] [Abstract][Full Text] [Related]
25. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
27. Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids.
Khalefa BI; Shaqura M; Al-Khrasani M; Fürst S; Mousa SA; Schäfer M
Eur J Pain; 2012 May; 16(5):690-705. PubMed ID: 22337491
[TBL] [Abstract][Full Text] [Related]
28. Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists.
Sevostianova N; Danysz W; Bespalov AY
Eur J Pharmacol; 2005 Nov; 525(1-3):83-90. PubMed ID: 16297905
[TBL] [Abstract][Full Text] [Related]
29. Stimulation of mu and delta opioid receptors induces hyperalgesia while stimulation of kappa receptors induces antinociception in the hot plate test in the naked mole-rat (Heterocephalus glaber).
Towett PK; Kanui TI; Juma FD
Brain Res Bull; 2006 Dec; 71(1-3):60-8. PubMed ID: 17113929
[TBL] [Abstract][Full Text] [Related]
30. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
31. Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors.
di Bosco AM; Grieco P; Diurno MV; Campiglia P; Novellino E; Mazzoni O
Chem Biol Drug Des; 2008 Apr; 71(4):328-35. PubMed ID: 18284554
[TBL] [Abstract][Full Text] [Related]
32. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
34. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
[TBL] [Abstract][Full Text] [Related]
36. The role of gonadal hormones on opioid receptor protein density in arthritic rats.
Kren MC; Haller VL; Welch SP
Eur J Pharmacol; 2008 Jan; 578(2-3):177-84. PubMed ID: 18054782
[TBL] [Abstract][Full Text] [Related]
37. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
[TBL] [Abstract][Full Text] [Related]
38. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
Narita M; Miyoshi K; Narita M; Suzuki T
Neuroscience; 2007 Feb; 144(3):777-82. PubMed ID: 17156932
[TBL] [Abstract][Full Text] [Related]
39. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
40. Studies with ketamine and alfentanil following Freund's complete adjuvant-induced inflammation in rats.
Edwards SR; Mather LE; Smith MT
Clin Exp Pharmacol Physiol; 2007; 34(5-6):414-20. PubMed ID: 17439409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
